Maze Therapeutics Inc (MAZE)
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule precision medicines for kidney and metabolic diseases in the United States. Its pipeline includes MZE829, an oral APOL1 inhibitor being evaluated in a phase II clinical trial for APOL1 kidney disease, and MZE782, an oral small-molecule inhibitor that is phase II ready for phenylketonuria and chronic kidney disease. The company is also advancing MZE001, an investigational oral inhibitor in development for Pompe disease. Maze Therapeutics has entered collaboration and license agreements with Trace Neuroscience, Shionogi & Co., and Neurocrine Biosciences covering research programs tied to UNC13A, MZE001, and ATXN2. Founded in 2017 and formerly known as Modulus Therapeutics, Inc., the company is based in South San Francisco, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MAZE
|
$22.72
|
-30.2% Downside
|
Overvalued
|
$62.54
|
92.2% Upside
|
Bargain
|
Good
|
0.0%
|
3.9x
|
87.7x
|
1.754 B
|
1.32 B
|
3.3%
|
65.2%
|
12.0
|
80.0%
|
